News/ News/ R&D NGM craters after dropping mid-stage NASH candidate aldafermin Phil Taylor fibrosis, hepatology, NASH, NGM Bio 0 Comment Shares in NGM Biopharma have plummeted after the US biotech said it would abandon development of aldafermin in Share X NGM craters after dropping mid-stage NASH candidate aldafermin https://pharmaphorum.com/news/ngm-craters-after-dropping-mid-stage-nash-candidate-aldafermin/
